Igaz P, Tömböl Z, Szabó PM, et al. Steroid biosynthesis inhibitors in the therapy of hypercortisolism: theory and practice. Curr Med Chem. 2008;15(26):2734–47.
Hakami OA, Ahmed S, Karavitaki N. Epidemiology and mortality of Cushing's syndrome. Best Pract Res Clin Endocrinol Metab. 2021;35(1):101521.
Lacroix A, Feelders RA, Stratakis CA, et al. Cushing’s syndrome. Lancet. 2015;386(9996):913–27.
Nieman LK, Biller BM, Findling JW, et al. Treatment of Cushing’s syndrome: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(8):2807–31.
Ceccato F, Zilio M, Barbot M, et al. Metyrapone treatment in Cushing’s syndrome: a real-life study. Endocrine. 2018;62(3):701–11.
HRA Pharma Rare Diseases. Metopirone®(metyrapone): summary of product characteristics. 2020. http://www.hpra.ie/img/uploaded/swedocuments/Licence_PA22888-001-001_25082020125137.pdf. Accessed 28 June 2021.
HRA Pharma Rare Diseases. Metopirone®(metyrapone) capsules: US prescribing information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/012911s036lbl.pdf. Accessed 28 June 2021.
Comi RJ, Gorden P. Long-term medical treatment of ectopic ACTH syndrome. South Med J. 1998;91(11):1014–8.
Dickstein G, Lahav M, Shen-Orr Z, et al. Primary therapy for Cushing’s disease with metyrapone. JAMA. 1986;255(9):1167–9.
Gartner LA, Voorhess ML. Adrenocorticotropic hormone-producing thymic carcinoid in a teenager. Cancer. 1993;71(1):106–11.
Gillis D, Rösler A, Hannon TS, et al. Prolonged remission of severe Cushing syndrome without adrenalectomy in an infant with McCune-Albright syndrome. J Pediatr. 2008;152(6):882-4.e4.
Halioui-Louhaichi S, Dridi Y, Azzabi O, et al. Recovery of Cushing syndrome revealing McCune-Albright syndrome. Arch Pediatr. 2016;23(1):61–5.
Hána V, Dokoupilová M, Marek J, et al. Recurrent ACTH-independent Cushing’s syndrome in multiple pregnancies and its treatment with metyrapone. Clin Endocrinol (Oxf). 2001;54(2):277–81.
Jeffcoate WJ, Rees LH, Tomlin S, et al. Metyrapone in long-term management of Cushing’s disease. Br Med J. 1977;2(6081):215–7.
Jeffcoate WJ, Silverstone JT, Edwards CR, et al. Psychiatric manifestations of Cushing’s syndrome: response to lowering of plasma cortisol. Q J Med. 1979;48(191):465–72.
Littley MD, Shalet SM, Beardwell CG, et al. Long-term follow-up of low-dose external pituitary irradiation for Cushing’s disease. Clin Endocrinol (Oxf). 1990;33(4):445–55.
Lourenço R, Dias P, Gouveia R, et al. Neonatal McCune-Albright syndrome with systemic involvement: a case report. J Med Case Rep. 2015;9:189.
Luca PD, Oren A, Somers GR, et al. The search for ectopic ACTH production in a 9-year-old boy. J Pediatr Endocrinol Metab. 2013;26(7–8):781–3.
Rydzewska M, Krawczuk-Rybak M, Zajkowska A, et al. Cushing’s syndrome in infancy due to ectopic ACTH secretion by a sacro-coccygeal teratoma. J Pediatr Endocrinol Metab. 2017;30(4):475–8.
Storr HL, Mitchell H, Swords FM, et al. Clinical features, diagnosis, treatment and molecular studies in paediatric Cushing’s syndrome due to primary nodular adrenocortical hyperplasia. Clin Endocrinol (Oxf). 2004;61(5):553–9.
Verbeeten K, Hadjiyannakis S, Cameron M, et al. Rectal metyrapone for treatment of hypercortisolism in an infant with McCune-Albright syndrome. J Pediatr Pharmacol Ther. 2017;22(3):233–6.
Vieira H, Brain C. Cushing syndrome associated with an adrenal tumour. BMJ Case Rep. 2012. https://doi.org/10.1136/bcr-2012-006685.
Wojcik M, Kalicka-Kasperczyk A, Luszawska-Kutrzeba T, et al. The first description of metyrapone use in severe Cushing Syndrome due to ectopic ACTH secretion in an infant with immature sacrococcygeal teratoma. Case report. Neuro Endocrinol Lett. 2015;36(7):653–5.
Beardwell CG, Adamson AR, Shalet SM. Prolonged remission in florid Cushing’s syndrome following metyrapone treatment. Clin Endocrinol (Oxf). 1981;14(5):485–92.
Doi M, Sugiyama T, Izumiyama H, et al. Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J. 2010;57(12):1061–9.
Donckier J, Burrin JM, Ramsay ID, et al. Successful control of Cushing’s disease in the elderly with long term metyrapone. Postgrad Med J. 1986;62(730):727–30.
Hotham NJ, Ilett KF, Hackett LP, et al. Transfer of metyrapone and its metabolite, rac-metyrapol, into breast milk. J Hum Lact. 2009;25(4):451–4.
Achong N, D’Emden M, Fagermo N, et al. Pregnancy-induced Cushing’s syndrome in recurrent pregnancies: case report and literature review. Aust N Z J Obstet Gynaecol. 2012;52(1):96–100.
Blanco C, Maqueda E, Rubio JA, et al. Cushing’s syndrome during pregnancy secondary to adrenal adenoma: metyrapone treatment and laparoscopic adrenalectomy. J Endocrinol Investig. 2006;29(2):164–7.
Kamenický P, Droumaguet C, Salenave S, et al. Mitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab. 2011;96(9):2796–804.
Lim WH, Torpy DJ, Jeffries WS. The medical management of Cushing’s syndrome during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2013;168(1):1–6.
Lindsay JR, Jonklaas J, Oldfield EH, et al. Cushing’s syndrome during pregnancy: personal experience and review of the literature. J Clin Endocrinol Metab. 2005;90(5):3077–83.
Zieleniewski W, Michalak R. A successful case of pregnancy in a woman with ACTH-independent Cushing’s syndrome treated with ketoconazole and metyrapone. Gynecol Endocrinol. 2017;33(5):349–52.
Diri H, Bayram F, Simsek Y, et al. A pregnant woman who underwent laparoscopic adrenalectomy due to Cushing's syndrome. Case Rep Endocrinol. 2014;2014:283458.
Klibanski A, Stephen AE, Greene MF, et al. Case records of the Massachusetts General Hospital. Case 36-2006. A 35-year-old pregnant woman with new hypertension. N Engl J Med. 2006;355(21):2237–45.
Cabezon C, Bruno OD, Cohen M, et al. Twin pregnancy in a patient with Cushing’s disease. Fertil Steril. 1999;72(2):371–2.
Close CF, Mann MC, Watts JF, et al. ACTH-independent Cushing’s syndrome in pregnancy with spontaneous resolution after delivery: control of the hypercortisolism with metyrapone. Clin Endocrinol (Oxf). 1993;39(3):375–9.
Connell JM, Cordiner J, Davies DL, et al. Pregnancy complicated by Cushing’s syndrome: potential hazard of metyrapone therapy. Case report Br J Obstet Gynaecol. 1985;92(11):1192–5.
Gormley MJ, Hadden DR, Kennedy TL, et al. Cushing’s syndrome in pregnancy—treatment with metyrapone. Clin Endocrinol (Oxf). 1982;16(3):283–93.
Wallace C, Toth EL, Lewanczuk RZ, et al. Pregnancy-induced Cushing’s syndrome in multiple pregnancies. J Clin Endocrinol Metab. 1996;81(1):15–21.
Kasperlik-Zaluska AA, Szczupacka I, Leszczynska-Bystrzanowska J, et al. Pregnancy-dependent Cushing’s syndrome in three pregnancies. BJOG. 2000;107(6):810–2.
Galinsky RE, Nelson EB, Rollins DE. Pharmacokinetic consequences and toxicologic implications of metyrapone-induced alterations of acetaminophen elimination in man. Eur J Clin Pharmacol. 1987;33(4):391–6.
Rigel DF, Fu F, Beil M, et al. Pharmacodynamic and pharmacokinetic characterization of the aldosterone synthase inhibitor FAD286 in two rodent models of hyperaldosteronism: comparison with the 11beta-hydroxylase inhibitor metyrapone. J Pharmacol Exp Ther. 2010;334(1):232–43.
Daniel E, Newell-Price JD. Therapy of endocrine disease: steroidogenesis enzyme inhibitors in Cushing’s syndrome. Eur J Endocrinol. 2015;172(6):R263–80.
Creemers SG, Feelders RA, de Jong FH, et al. Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study. J Clin Endocrinol Metab. 2019;104(8):3437–49.
Sampath-Kumar R, Yu M, Khalil MW, et al. Metyrapone is a competitive inhibitor of 11beta-hydroxysteroid dehydrogenase type 1 reductase. J Steroid Biochem Mol Biol. 1997;62(2–3):195–9.
Blichert-Toft M, Folke K, Nielsen ML. Effects of metyrapone and corticotropin infusion on cortisol disappearance rate in man. J Clin Endocrinol Metab. 1972;35(1):59–62.
Levin J, Zumoff B, Fukushima DK. Extraadrenal effects of metyrapone in man. J Clin Endocrinol Metab. 1978;47(4):845–9.
Schöneshöfer M, Schefzig B, Arabin S. Short-term kinetics of serum adrenal steroids and plasma ACTH after a single dose of metyrapone in man. J Endocrinol Invest. 1980;3(3):229–36.
Sprunt JG, Browning MC, Hannah DM. Some aspects of the pharmacology of metyrapone. Proc R Soc Med. 1967;60(9):908–9.
Halsall DJ, Gurnell M. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2012;49(2):204.
Monaghan PJ, Owen LJ, Trainer PJ, et al. Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11beta-hydroxylase inhibitor metyrapone. Ann Clin Biochem. 2011;48(5):441–6.
Owen LJ, Halsall DJ, Keevil BG. Cortisol measurement in patients receiving metyrapone therapy. Ann Clin Biochem. 2010;47(6):573–5.
European Medicines Agency. Ketoconazole HRA: public assessment report. 2015. https://www.ema.europa.eu/en/documents/assessment-report/ketoconazole-hra-epar-public-assessment-report_en.pdf. Accessed 28 Jun 2021.
Data on file, HRA Pharma Rare Diseases, 2020.
Nieman L, Boscaro M, Scaroni C, et al. PROMPT: a prospective study to assess efficacy and safety of metyrapone in endogenous Cushing's syndrome - 12-week interim analysis [poster no. 1107]. In: 22nd European Congress of Endocrinology; 2020.
Nieman LK, Boscaro M, Scaroni CM, et al. Metyrapone treatment in endogenous Cushing’s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III/IV study. J Endocr Soc. 2021;5(Suppl_1):A515.
Data on file, HRA Pharma Rare Diseases, 2021.
Daniel E, Aylwin S, Mustafa O, et al. Effectiveness of metyrapone in treating Cushing’s syndrome: a retrospective multicenter study in 195 patients. J Clin Endocrinol Metab. 2015;100(11):4146–54.
Valassi E, Crespo I, Gich I, et al. A reappraisal of the medical therapy with steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf). 2012;77(5):735–42.
van den Bosch OF, Stades AM, Zelissen PM. Increased long-term remission after adequate medical cortisol suppression therapy as presurgical treatment in Cushing’s disease. Clin Endocrinol (Oxf). 2014;80(2):184–90.
Obinata D, Yamaguchi K, Hirano D, et al. Preoperative management of Cushing’s syndrome with metyrapone for severe psychiatric disturbances. Int J Urol. 2008;15(4):361–2.
Vassiliadi DA, Tsagarakis S. Diagnosis and management of primary bilateral macronodular adrenal hyperplasia. Endocr Relat Cancer. 2019;26(10):R567–81.
Omori N, Nomura K, Omori K, et al. Rational, effective metyrapone treatment of ACTH-independent bilateral macronodular adrenocortical hyperplasia (AIMAH). Endocr J. 2001;48(6):665–9.
Yoshida M, Umeda H, Iwama S, et al. Assessment of long-term efficacy and safety of metyrapone monotherapy in a patient with ACTH-independent macronodular adrenal hyperplasia. Endocrine. 2012;41(1):160–1.
Halioui-Louhaichi S, Azzabi O, Nefzi L, et al. Treatment with metyrapone of Cushing’s syndrome revealing McCune-Albright syndrome. Arch Pediatr. 2005;12(7):1120–3.
Debono M, Harrison R, Chadarevian R, et al. Resetting the abnormal circadian cortisol rhythm in adrenal incidentaloma patients with mild autonomous cortisol secretion. J Clin Endocrinol Metab. 2017;102(9):3461–9.
Puglisi S, Perotti P, Barbot M, et al. Preoperative treatment with metyrapone in patients with Cushing’s syndrome due to adrenal adenoma: a pilot prospective study. Endocr Connect. 2018;7(11):1227–35.
Corcuff JB, Young J, Masquefa-Giraud P, et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015;172(4):473–81.
Verhelst JA, Trainer PJ, Howlett TA, et al. Short and long-term responses to metyrapone in the medical management of 91 patients with Cushing’s syndrome. Clin Endocrinol (Oxf). 1991;35(2):169–78.
Thorén M, Adamson U, Sjöberg HE. Aminoglutethimide and metyrapone in the management of Cushing’s syndrome. Acta Endocrinol (Copenh). 1985;109(4):451–7.
Britton S, Thoren M, Sjoberg HE. The immunological hazard of Cushing’s syndrome. Br Med J. 1975;4(5998):678–80.
Child DF, Burke CW, Burley DM, et al. Drug controlled of Cushing's syndrome. Combined aminoglutethimide and metyrapone therapy. Acta Endocrinol (Copenh). 1976;82(2):330–41.
Beck KR, Thompson GR, 3rd, Odermatt A. Drug-induced endocrine blood pressure elevation. Pharmacol Res. 2020;154:104311.
Valassi E, Aulinas A, Glad CA, et al. A polymorphism in the CYP17A1 gene influences the therapeutic response to steroidogenesis inhibitors in Cushing’s syndrome. Clin Endocrinol (Oxf). 2017;87(5):433–9.
Newell-Price J, Pivonello R, Tabarin A, et al. Use of late-night salivary cortisol to monitor response to medical treatment in Cushing’s disease. Eur J Endocrinol. 2020;182(2):207–17.
Kann PH, Munzel M, Hadji P, et al. Alterations of cortisol homeostasis may link changes of the sociocultural environment to an increased diabetes and metabolic risk in developing countries: a prospective diagnostic study performed in cooperation with the Ovahimba people of the Kunene region/northwestern Namibia. J Clin Endocrinol Metab. 2015;100(3):E482–6.
Kumari M, Shipley M, Stafford M, et al. Association of diurnal patterns in salivary cortisol with all-cause and cardiovascular mortality: findings from the Whitehall II study. J Clin Endocrinol Metab. 2011;96(5):1478–85.
Yoshida K, Fukuoka H, Odake Y, et al. Multiple salivary cortisol measurements are a useful tool to optimize metyrapone treatment in patients with Cushing’s syndromes treatment: case presentations. Front Endocrinol (Lausanne). 2017;8:375.